Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

Luisa Munoz-Price, Laurent Poirel, Robert A. Bonomo, Mitchell J. Schwaber, George L. Daikos, Martin Cormican, Giuseppe Cornaglia, Javier Garau, Marek Gniadkowski, Mary K. Hayden, Karthikeyan Kumarasamy, David M. Livermore, Juan J. Maya, Patrice Nordmann, Jean B. Patel, David L. Paterson, Johann Pitout, Maria Virginia Villegas, Hui Wang, Neil WoodfordJohn P. Quinn

Research output: Contribution to journalArticle

709 Citations (Scopus)

Abstract

Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile β-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.

Original languageEnglish
Pages (from-to)785-796
Number of pages12
JournalThe Lancet Infectious Diseases
Volume13
Issue number9
DOIs
StatePublished - Sep 1 2013

Fingerprint

Klebsiella pneumoniae
Colistin
Epidemiology
Infection Control
Anti-Bacterial Agents
Mortality
Imipenem
Aminoglycosides
Drug Combinations
Bacteremia
Gram-Negative Bacteria
Pneumonia
Survival
Pharmaceutical Preparations
tigecycline
Therapeutics

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Munoz-Price, L., Poirel, L., Bonomo, R. A., Schwaber, M. J., Daikos, G. L., Cormican, M., ... Quinn, J. P. (2013). Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases, 13(9), 785-796. https://doi.org/10.1016/S1473-3099(13)70190-7

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. / Munoz-Price, Luisa; Poirel, Laurent; Bonomo, Robert A.; Schwaber, Mitchell J.; Daikos, George L.; Cormican, Martin; Cornaglia, Giuseppe; Garau, Javier; Gniadkowski, Marek; Hayden, Mary K.; Kumarasamy, Karthikeyan; Livermore, David M.; Maya, Juan J.; Nordmann, Patrice; Patel, Jean B.; Paterson, David L.; Pitout, Johann; Villegas, Maria Virginia; Wang, Hui; Woodford, Neil; Quinn, John P.

In: The Lancet Infectious Diseases, Vol. 13, No. 9, 01.09.2013, p. 785-796.

Research output: Contribution to journalArticle

Munoz-Price, L, Poirel, L, Bonomo, RA, Schwaber, MJ, Daikos, GL, Cormican, M, Cornaglia, G, Garau, J, Gniadkowski, M, Hayden, MK, Kumarasamy, K, Livermore, DM, Maya, JJ, Nordmann, P, Patel, JB, Paterson, DL, Pitout, J, Villegas, MV, Wang, H, Woodford, N & Quinn, JP 2013, 'Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases', The Lancet Infectious Diseases, vol. 13, no. 9, pp. 785-796. https://doi.org/10.1016/S1473-3099(13)70190-7
Munoz-Price L, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases. 2013 Sep 1;13(9):785-796. https://doi.org/10.1016/S1473-3099(13)70190-7
Munoz-Price, Luisa ; Poirel, Laurent ; Bonomo, Robert A. ; Schwaber, Mitchell J. ; Daikos, George L. ; Cormican, Martin ; Cornaglia, Giuseppe ; Garau, Javier ; Gniadkowski, Marek ; Hayden, Mary K. ; Kumarasamy, Karthikeyan ; Livermore, David M. ; Maya, Juan J. ; Nordmann, Patrice ; Patel, Jean B. ; Paterson, David L. ; Pitout, Johann ; Villegas, Maria Virginia ; Wang, Hui ; Woodford, Neil ; Quinn, John P. / Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. In: The Lancet Infectious Diseases. 2013 ; Vol. 13, No. 9. pp. 785-796.
@article{41c065b8c3a3419c907d3aa52fefcad0,
title = "Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases",
abstract = "Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile β-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.",
author = "Luisa Munoz-Price and Laurent Poirel and Bonomo, {Robert A.} and Schwaber, {Mitchell J.} and Daikos, {George L.} and Martin Cormican and Giuseppe Cornaglia and Javier Garau and Marek Gniadkowski and Hayden, {Mary K.} and Karthikeyan Kumarasamy and Livermore, {David M.} and Maya, {Juan J.} and Patrice Nordmann and Patel, {Jean B.} and Paterson, {David L.} and Johann Pitout and Villegas, {Maria Virginia} and Hui Wang and Neil Woodford and Quinn, {John P.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1016/S1473-3099(13)70190-7",
language = "English",
volume = "13",
pages = "785--796",
journal = "The Lancet Infectious Diseases",
issn = "1473-3099",
publisher = "Lancet Publishing Group",
number = "9",

}

TY - JOUR

T1 - Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

AU - Munoz-Price, Luisa

AU - Poirel, Laurent

AU - Bonomo, Robert A.

AU - Schwaber, Mitchell J.

AU - Daikos, George L.

AU - Cormican, Martin

AU - Cornaglia, Giuseppe

AU - Garau, Javier

AU - Gniadkowski, Marek

AU - Hayden, Mary K.

AU - Kumarasamy, Karthikeyan

AU - Livermore, David M.

AU - Maya, Juan J.

AU - Nordmann, Patrice

AU - Patel, Jean B.

AU - Paterson, David L.

AU - Pitout, Johann

AU - Villegas, Maria Virginia

AU - Wang, Hui

AU - Woodford, Neil

AU - Quinn, John P.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile β-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.

AB - Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile β-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.

UR - http://www.scopus.com/inward/record.url?scp=84882712084&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882712084&partnerID=8YFLogxK

U2 - 10.1016/S1473-3099(13)70190-7

DO - 10.1016/S1473-3099(13)70190-7

M3 - Article

C2 - 23969216

AN - SCOPUS:84882712084

VL - 13

SP - 785

EP - 796

JO - The Lancet Infectious Diseases

JF - The Lancet Infectious Diseases

SN - 1473-3099

IS - 9

ER -